Skip to content

Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies

Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies 1

The efficacy of CsA in plaque psoriasis has been evidenced by several randomized studies, which also showed the dosage-dependent therapeutic effects, using the drug at dosages ranging from 1. Efficacy of low-dose cyclosporin A in sporiasis: results of dose-finding studies, British Journal of Dermatology, vol. Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherland was found in Unbound MEDLINE. In studies of oral MTX given at doses of 15 to 20 mg weekly for patients with moderate to severe plaque psoriasis, approximately 50 to 60 of patients achieved a PASI-75 response whereas up to 30 experienced adverse effects, including gastrointestinal side effects, hepatotoxicity, bone-marrow suppression, acute pneumonitis, and pulmonary fibrosis that necessitated discontinuation of therapy. G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies.

Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies 2Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. G. Efficacy of low-dose cyclosporine A in psoriasis: results of dose-finding studies. K.H., Dubertret, L. Efficacy and safety of oral cyclosporine in psoriasis. Management of Plaque Psoriasis with Low-Dose Cyclosporin. F. In an open multicenter study, cyclosporin (CsA) at low doses (3 mg/kg/day adjusted during the course of treatment on the basis of clinical response and tolerability up to a maximum of 5 mg/kg/day) was given to 293 evaluable patients with severe plaque-form psoriasis (M/F 215/78, aged 19 80 years, 2 53 years from diagnosis) in order to evaluate its safety and efficacy over a median follow-up of 7 months of treatment and 3 months after treatment. Abeywickrama K, Laburte C, von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies.

Timonen P, Friend D, Abeywickrama K, Laburte C, Von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study. This study will evaluate the efficacy and safety of two concentrations (0.5 percent and 1 ) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque psoriasis. 5 percent and 1 ) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque psoriasis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and dosing frequency in future clinical safety and efficacy studies. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and dosing frequency in future clinical safety and efficacy studies.

References In The Use Of Cyclosporine In Dermatology: Part I

Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies 3These results were compared to those from other studies identified by a Medline search. A greater percentage of patients achieved 75 improvement with the UVB laser treatments than was reported for other forms of phototherapy or systemic therapy with acitretin or low dose cyclosporine, and did so more rapidly. Low-dose ciclosporin therapy seems to be insufficient for maintaining disease control. Conclusions: Obese patients with moderate-to-severe psoriasis increase their response to low-dose cyclosporine if a calorie-controlled diet is included in the treatment regimen. Because obesity is on the increase and is frequently associated with psoriasis, further studies will be necessary to elucidate the relation between the effect of weight loss in psoriasis patients receiving traditional or biological therapies.

John Libbey Eurotext